<DOC>
	<DOCNO>NCT00694083</DOCNO>
	<brief_summary>A clinical study evaluate safety , tolerability , pharmacokinetics ridaforolimus ( MK-8669 ) participant locally advance metastatic solid tumor .</brief_summary>
	<brief_title>Study Ridaforolimus ( MK-8669 ) Participants With Solid Tumors ( MK-8669-003 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically Or Cytologically Confirmed Metastatic Or Locally Advanced Solid Tumors That Have Failed To Respond To Standard Therapy , Or For Which Adequate Standard Therapy Does Not Exist Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Adequate Organ Function Participant Who Has Had Chemotherapy , Radiotherapy , Or Biological Therapy Within 4 Weeks ( 6 Weeks For Nitrosoureas Or Mitomycin C ) Prior To Registration Any central nervous system Metastasis Which Has Symptoms Or Requires Treatment Any Primary Central Nervous System Tumor Any Symptomatic Ascites Or Plural Effusion Which Requires Treatment A History Or Current Evidence Of Any Clinically Significant Disease That Might Confound The Results Of The Study , Complicate The Interpretation Of The Study Results , Interfere With The Participant 's Participation , Or Pose An Additional Risk To The Participant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>